ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary

LEUVEN, Belgium, May 24, 2017 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it will give a presentation at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting, which is being held in Budapest, Hungary from May 25-27.

The presentation "Targeting placental growth factor attenuates retinal permeability and inflammation in diabetic Akimba mice" which will be given by ThromboGenics' scientist Dr. Tjing-Tjing Hu, will provide further pre-clinical evidence supporting the development of THR-317. The presentation will take place at 10.00am CET, Friday 26 May.

THR-317 is a monoclonal antibody targeting placental growth factor (PlGF), which is being developed for the treatment of diabetic macular edema (DME) as a stand-alone or as a combination therapy with current anti-VEGF drugs. ThromboGenics is currently recruiting patients into a Phase II clinical trial for THR-317 in Europe. First data from this study are expected in Q1 2018.  

"We are pleased to have the opportunity topresent our cutting-edge research in the field of diabetic eye diseaseat this important meeting", said Dr.Patrik De Haes, CEO of ThromboGenics nv."There is a clear unmet medical need for improved treatment options for diabetic eye disease. ThromboGenicsis focused on addressing this need and is developingmultiple new therapies, including THR-317,eachwiththe potential to improve on the current standard of care fora range of diabetic eye disease indications."

About ThromboGenics 

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy (NPDR).

ThromboGenics is conducting a Phase II clinical study evaluating THR- 317, a PlGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or as a combination therapy with anti-VEGF treatments. In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.

ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of symptomatic vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US. Novartis commercializes JETREA® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.  

More information is available at http://www.thrombogenics.com

Important information about forward-looking statements 

Certain statements in this press release may be considered"forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.  

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws. 

For further information please contact:
ThromboGenics
Wouter Piepers,
Global Head of Corporate Communications & IR
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@thrombogenics.com

Citigate Dewe Rogerson
David Dible/Sylvie Berrebi
Tel: +44 20 7282 9571
david.dible@citigatedr.co.uk
sylvie.berrebi@citigatedr.co.uk